Eidos Therapeutics Stock Forecast, Price & News

Eidos Therapeutics' stock was trading at $43.89 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, EIDX shares have increased by 61.6% and is now trading at $70.92.
View which stocks have been most impacted by COVID-19.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eidos Therapeutics in the last year. There are currently 1 sell rating, 7 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Eidos Therapeutics.

Eidos Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, February 24th 2021.
View our earnings forecast for Eidos Therapeutics.

Eidos Therapeutics, Inc. (NASDAQ:EIDX) posted its earnings results on Thursday, October, 29th. The company reported ($0.79) EPS for the quarter, missing the Zacks' consensus estimate of ($0.71) by $0.08. The business had revenue of $0.13 million for the quarter.
View Eidos Therapeutics' earnings history.

10 brokers have issued 1-year price objectives for Eidos Therapeutics' shares. Their forecasts range from $34.00 to $80.00. On average, they expect Eidos Therapeutics' stock price to reach $60.58 in the next twelve months. This suggests that the stock has a possible downside of 14.6%.
View analysts' price targets for Eidos Therapeutics.

Eidos Therapeutics saw a decrease in short interest in the month of October. As of October 15th, there was short interest totaling 809,400 shares, a decrease of 58.5% from the September 30th total of 1,950,000 shares. Based on an average daily trading volume, of 180,800 shares, the short-interest ratio is presently 4.5 days. Currently, 6.1% of the company's shares are short sold.
View Eidos Therapeutics' Short Interest.

Some companies that are related to Eidos Therapeutics include Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Mirati Therapeutics (MRTX), Teva Pharmaceutical Industries (TEVA), Ascendis Pharma A/S (ASND), CureVac B.V. (CVAC), Jazz Pharmaceuticals (JAZZ), Galapagos (GLPG), Mylan (MYL), ACADIA Pharmaceuticals (ACAD), Ionis Pharmaceuticals (IONS), Ultragenyx Pharmaceutical (RARE), Perrigo (PRGO), United Therapeutics (UTHR) and Arrowhead Pharmaceuticals (ARWR).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Eidos Therapeutics investors own include Exelixis (EXEL), Crispr Therapeutics (CRSP), Aduro Biotech (ADRO), Micron Technology (MU), Pfizer (PFE), Verastem (VSTM), ImmunoGen (imgn), Nabriva Therapeutics (NBRV), Occidental Petroleum (OXY) and Axsome Therapeutics (AXSM).

(EIDX) raised $101 million in an IPO on Wednesday, June 20th 2018. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Barclays was co-manager.

Eidos Therapeutics trades on the NASDAQ under the ticker symbol "EIDX."

Eidos Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include DekaBank Deutsche Girozentrale (0.04%) and BNP Paribas Arbitrage SA (0.01%). Company insiders that own Eidos Therapeutics stock include Bridgebio Pharma Llc, Bridgebio Pharma, Inc, Cameron Turtle, Christine Siu, Eric Aguiar, Franco Valle, Jonathan C Fox and Uma Sinha.
View institutional ownership trends for Eidos Therapeutics.

EIDX stock was purchased by a variety of institutional investors in the last quarter, including DekaBank Deutsche Girozentrale, and BNP Paribas Arbitrage SA. Company insiders that have bought Eidos Therapeutics stock in the last two years include Bridgebio Pharma Llc, Bridgebio Pharma, Inc, and Eric Aguiar.
View insider buying and selling activity for Eidos Therapeutics.

Shares of EIDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of EIDX stock can currently be purchased for approximately $70.92.

Eidos Therapeutics has a market capitalization of $2.74 billion and generates $26.69 million in revenue each year. The company earns $-37,830,000.00 in net income (profit) each year or ($1.03) on an earnings per share basis. Eidos Therapeutics employs 64 workers across the globe.

The official website for Eidos Therapeutics is www.eidostx.com.

Eidos Therapeutics' mailing address is 101 MONTGOMERY STREET SUITE 2550, SAN FRANCISCO CA, 94104. The company can be reached via phone at 415-887-1471 or via email at [email protected]